ALK-Abello A/S 2023 AR2
The report highlights ALK-Abelló's financial and strategic progress in 2023, delivering a 9% organic revenue growth to DKK 4,824 million and a 50% increase in operating profit (EBIT) to DKK 666 million. The company treated 2.4 million patients and expanded its tablet portfolio, including successful Phase 3 paediatric trials for house dust mite and tree pollen tablets. In sustainability, ALK set science-based CO2 reduction targets validated by the SBTi, committing to a 42% reduction in Scope 1 and 2 emissions by 2030. Additionally, the company maintained high employee engagement, scoring 8.4 out of 10, and achieved 42% representation of the underrepresented gender in management.
Company: ALK-Abello A/S
Sector: Manufacturing
Country: Denmark
Year: 2023
Type: AR2
Pages: 116
ALK-Abello A/S
The report highlights ALK-Abelló's financial and strategic progress in 2023, delivering a 9% organic revenue growth to DKK 4,824 million and a 50% increase in operating profit (EBIT) to DKK 666 million. The company treated 2.4 million patients and expanded its tablet portfolio, including successful Phase 3 paediatric trials for house dust mite and tree pollen tablets. In sustainability, ALK set science-based CO2 reduction targets validated by the SBTi, committing to a 42% reduction in Scope 1 and 2 emissions by 2030. Additionally, the company maintained high employee engagement, scoring 8.4 out of 10, and achieved 42% representation of the underrepresented gender in management.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Employees